- End-stage renal disease, with patients receiving a primary or secondary renal
allograft from a cadaveric donor, from a living-unrelated donor, or from a
living-related (excluding 0 antigen mismatch) donor.
- Women who are of childbearing potential must have a negative pregnancy test before
sirolimus administration and agree to use a medically acceptable method of
contraception throughout the treatment period and for 3 months following
discontinuation of sirolimus
- Evidence of active systemic or localized major infection at the time of initial
sirolimus administration
- Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during
pre-study screening.
- Chronic antiarrhythmic therapy for ventricular arrhythmia or other cardiac abnormality
contraindicating general anesthesia or surgery